Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Gal S, Zheng H, Fridkin M, Youdim MB.

Neurotox Res. 2010 Jan;17(1):15-27. doi: 10.1007/s12640-009-9070-9. Epub 2009 Jul 16.

PMID:
19609632
2.

M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.

Youdim MB.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S151-4. doi: 10.1016/S1353-8020(11)70047-5. Review.

PMID:
22166418
3.

The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.

Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T.

Neuropharmacology. 2015 Oct;97:86-94. doi: 10.1016/j.neuropharm.2015.05.015. Epub 2015 May 23.

PMID:
26006269
4.

Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.

Gao L, Díaz-Martín J, Dillmann WH, López-Barneo J.

Neuroscience. 2011 Oct 13;193:323-9. doi: 10.1016/j.neuroscience.2011.07.028. Epub 2011 Jul 20.

PMID:
21782904
5.

Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.

Kurosaki R, Muramatsu Y, Kato H, Watanabe Y, Imai Y, Itoyama Y, Araki T.

Eur Neuropsychopharmacol. 2005 Jan;15(1):57-67.

PMID:
15572274
6.

Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.

Choi DY, Lee MK, Hong JT.

Neurobiol Dis. 2013 Jan;49:159-68. doi: 10.1016/j.nbd.2012.08.001. Epub 2012 Aug 10.

PMID:
22922220
7.

Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.

Liu LX, Chen WF, Xie JX, Wong MS.

Neurosci Res. 2008 Feb;60(2):156-61. Epub 2007 Oct 23.

PMID:
18054104
9.

Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.

Mitsumoto Y, Watanabe A, Mori A, Koga N.

Biochem Biophys Res Commun. 1998 Jul 30;248(3):660-3.

PMID:
9703982
10.
11.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
12.

Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.

Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1243-50. doi: 10.1016/j.pnpbp.2008.03.024. Epub 2008 Apr 7.

PMID:
18471948
13.

Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.

Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG.

J Neuroinflammation. 2012 Oct 23;9:241. doi: 10.1186/1742-2094-9-241.

14.

Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.

Breckenridge CB, Sturgess NC, Butt M, Wolf JC, Zadory D, Beck M, Mathews JM, Tisdel MO, Minnema D, Travis KZ, Cook AR, Botham PA, Smith LL.

Neurotoxicology. 2013 Jul;37:1-14. doi: 10.1016/j.neuro.2013.03.005. Epub 2013 Mar 21.

16.

Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B.

J Neuroinflammation. 2010 Nov 23;7:83. doi: 10.1186/1742-2094-7-83.

17.

EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.

Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO.

Eur J Neurosci. 2008 Jul;28(1):41-50. doi: 10.1111/j.1460-9568.2008.06314.x.

PMID:
18662333
18.

Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.

Kozina EA, Khakimova GR, Khaindrava VG, Kucheryanu VG, Vorobyeva NE, Krasnov AN, Georgieva SG, Kerkerian-Le Goff L, Ugrumov MV.

J Neurol Sci. 2014 May 15;340(1-2):198-207. doi: 10.1016/j.jns.2014.03.028. Epub 2014 Mar 21.

PMID:
24768159
19.

Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.

Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S.

Exp Neurol. 1994 Apr;126(2):195-204.

PMID:
7925820
20.

The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Benskey MJ, Manfredsson FP, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2015 Jan;46:1-11. doi: 10.1016/j.neuro.2014.11.004. Epub 2014 Nov 20.

Supplemental Content

Support Center